Results 31 to 40 of about 48,138 (255)

Safety of Daprodustat for the Treatment of Chronic Kidney Disease Anemia: Final Analysis of a Multicenter Postmarketing Surveillance Study in Japan

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Introduction This final analysis of a multicenter, prospective postmarketing surveillance study evaluated the safety of daprodustat in patients with chronic kidney disease anemia in routine clinical practice in Japan. Methods Patients who initiated daprodustat between September 2020 and July 2022 were registered.
Tadao Akizawa, Kyomi Kanaya, Kiyomi Aizawa, Masanori Onoki, Hirofumi Ozeki, Kazuko Suzuki, Ai Hayashi, Tomohiko Asamura   +7 more
wiley   +1 more source

Advances in neuro-immune interactions in chronic pruritic dermatoses

Pifu-xingbing zhenliaoxue zazhi, 2023
Chronic pruritus is a clinical manifestation of a variety of cutaneous and systemic diseases. Persist chronic pruritus leads to a decreased quality of life.
Xinran LI, Yao CHEN, Fengxian LI
doaj   +1 more source

Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Comparison With Rituximab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan, Lei Zhou, Jingzi ZhangBao, Hongmei Tan, Zhouzhou Wang, Chao Quan   +5 more
wiley   +1 more source

Dupilumab Improves Prurigo Activity and Severity in Patients with Prurigo Nodularis: A Post Hoc Analysis of Pooled Results from the PRIME and PRIME2 Trials

Dermatology and Therapy
Introduction Prurigo nodularis (PN) is a dermatological condition characterized by intensely itchy nodules. The Prurigo Activity and Severity (PAS) assessment tool is a clinician-reported questionnaire used in the phase 3 dupilumab trials.
Sonja Stander, Claudia Zeidler, Jerome Msihid, Melanie Makhija, Ashish Bansal, Simmi Wiggins, Joseph Zahn, Ryan B. Thomas, Donia Bahloul   +8 more
doaj   +1 more source

Quality of Life in Psoriasis Vulgaris: Use of the ItchyQoL Question­naire in a Secukinumab Phase III Trial in Patients with Psoriasis Vulgaris

Acta Dermato-Venereologica, 2019
Chronic pruritus is a bothersome symptom in psoriasis vulgaris and can profoundly reduce quality of life (QoL). In this exploratory analysis of the PSORITUS study, the impact of pruritus on QoL in 130 subjects with moderate-to-severe psoriasis was ...
Sonja Ständer, Sabine Steinke, Matthias Augustin, Dieter Metze, Karin Loser, Daniel Baeumer, Christian Sieder, Thomas Luger   +7 more
doaj   +1 more source

FGF13 Deficiency Ameliorates Paclitaxel‐Induced Neuropathic Pain by Inhibiting VASH1‐Mediated Microtubule Detyrosination to Promote Mitophagy

Advanced Science, EarlyView.
FGF13 is upregulated in DRG neurons of PIPNP model mice. DRG neuron‐specific knockout of FGF13 ameliorates PIPNP symptoms. Mechanistically, FGF13 potentiates microtubule detyrosination by promoting VASH1 binding to microtubules. FGF13 knockout suppresses VASH1‐mediated microtubule detyrosination and promotes α‐tubulin tyrosination.
Yiming Dong, Yidan Wang, Simeng Lv, Zishan Dong, Kaixi Zhi, Xiuhua Guo, Xuyan Li, Ruoxi Yu, Yiyi Zhang, Siyuan Cheng, Chuan Wang   +10 more
wiley   +1 more source

European S2k Guideline on Chronic Pruritus

Acta Dermato Venereologica, 2019
Pruritus is a frequent symptom in medicine. Population-based studies show that every 5th person in the general population has suffered from chronic pruritus at least once in the lifetime with a 12-month incidence of 7%. In patient populations its frequency is much higher depending on the underlying cause, ranging from around 25% in haemodialysis ...
Weisshaar E., Szepietowski J. C., Dalgard F. J., Garcovich S., Gieler U., Gimenez-Arnau A. M., Lambert J., Leslie T., Mettang T., Misery L., Savk E., Streit M., Tschachler E., Wallengren J., Stander S.   +14 more
openaire   +6 more sources

TOLLIP Inhibits Psoriasis Progression via Suppressing PKM2‐Mediated Glycolysis in Keratinocytes

Advanced Science, EarlyView.
In this study, we identify TOLLIP as a critical regulator of psoriasis pathogenesis through its modulation of glycolytic metabolism. Our findings establish the TOLLIP‐PKM2‐glycolysis axis as a key mechanism linking metabolic reprogramming to psoriasis pathogenesis, and propose TOLLIP as a promising therapeutic target.
Xiuhuan Jiang, Guoying Miao, Na Shen, Qingxia Han, Xiaoru Han, Zichang Qiao, Kexin Feng, Zhuo Tan, Yaguang Wang, Xiuhua Liu, Chen Wu, Zhenzhen Yan   +11 more
wiley   +1 more source

Chronic Itch Affects Patients’ Ability to Experience Pleasure: Anhedonia in Itchy Disorders

Acta Dermato-Venereologica
Anhedonia, the reduced ability to experience pleasure, is a prevalent symptom in various psychiatric disorders, but has not been investigated in dermatological conditions, particularly those characterized by chronic itch.
Aleksandra Stefaniak, Magdalena Berek-Zamorska, Claudia Zeidler, Sonja Ständer, Jacek C. Szepietowski   +4 more
doaj   +1 more source

Validation of the Itch Severity Item as a Measurement Tool for Pruritus in Patients with Psoriasis: Results from a Phase 3 Tofacitinib Program

Acta Dermato-Venereologica, 2017
Tofacitinib is an oral Janus kinase inhibitor. This post-hoc analysis aimed to investigate the psychometric properties of the Itch Severity Item (ISI), a numeric rating scale from 0 (no itching) to 10 (worst possible itching) for pruritus in psoriasis ...
Sonja Ständer, Thomas Luger, Joseph C. Cappelleri, Andrew G. Bushmakin, Carla Mamolo, Michael A. Zielinski, Anna M Tallman, Gil Yosipovitch   +7 more
doaj   +1 more source